The recently released results of the DEFINE trial showed that patients taking anacetrapib, from a new class of medication (CETP inhibitors) reduced their LDL cholesterol (bad cholesterol) by approximately 40%, and raised their HDL cholesterol (good) by 140%. This...
Recent Comments